SAB Biotherapeutics Appoints Mr. Conley, Details Public Disclosure
Company Announcements

SAB Biotherapeutics Appoints Mr. Conley, Details Public Disclosure

SAB Biotherapeutics (SABS) just unveiled an update.

The Company has announced the appointment of Mr. Conley through a press release on May 30, 2024. This information, while provided to the public, is not intended for legal liability under the Securities Exchange Act of 1934, nor is it to be included in any future securities filings unless explicitly stated.

For a thorough assessment of SABS stock, go to TipRanks’ Stock Analysis page.

Related Articles
GlobeNewswireSAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
TipRanks Auto-Generated NewsdeskSAB Biotherapeutics Advances in Type 1 Diabetes Immunotherapy Trial
TheFlySAB Biotherapeutics provides SAB-142 clinical trial progress update
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App